Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

NCT05741619 | Completed

• 1 other identifier: 897
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC). While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative. In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Conditions

Autoimmune Encephalitis

Keywords

anti-GABAbr; autoimmune encephalitis; outcome

Outcome Measures

Primary Outcomes (1)

• Modified-Rankin scale (mRS)

  Modified-Rankin scale (mRS) ranked from 0 (full autonomy) to 6 (death)

  At 60 month (after the beginning of the disease)

Study Arms (1)

Anti-GABABr encephalitis

This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.

Other: Long-term outcome

Interventions

Long-term outcome OTHER

Autonomy, physical examination, behavioural disorders

Anti-GABABr encephalitis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients of reference center on paraneoplastic neurological syndrom

You may qualify if:

• encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022.

You may not qualify if:

• tested positive to another onconeural antibody.

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes

Lyon, 69677, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Sera and CSF at the diagnosis have been stocked in biobank (samples are already stored in biobank repositories and collected as part of "good clinical practice")

MeSH Terms

Conditions

Autoimmune Diseases of the Nervous System

Condition Hierarchy (Ancestors)

Nervous System Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 14, 2023
• First Posted: February 23, 2023
• Study Start: January 1, 2022
• Primary Completion: June 1, 2022
• Study Completion: September 1, 2022
• Last Updated: February 23, 2023

Record last verified: 2023-02

Locations

FR (1)